Takeda discontinues alisertib Phase 3 trial in relapsed or refractory peripheral T-cell lymphoma
15 May 2015 | By Victoria White
Takeda has decided to discontinue the Phase 3 trial of alisertib (MLN8237) for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)...